vs
Side-by-side financial comparison of Loar Holdings Inc. (LOAR) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
Stoke Therapeutics, Inc. is the larger business by last-quarter revenue ($158.6M vs $131.8M, roughly 1.2× Loar Holdings Inc.). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs 9.5%, a 61.7% gap on every dollar of revenue. On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs 19.3%).
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
LOAR vs STOK — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $131.8M | $158.6M |
| Net Profit | $12.5M | $112.9M |
| Gross Margin | 52.1% | — |
| Operating Margin | 18.0% | 70.2% |
| Net Margin | 9.5% | 71.2% |
| Revenue YoY | 19.3% | 3661.1% |
| Net Profit YoY | 239.5% | 528.0% |
| EPS (diluted) | $0.13 | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $131.8M | — | ||
| Q3 25 | $126.8M | — | ||
| Q2 25 | $123.1M | — | ||
| Q1 25 | $114.7M | $158.6M | ||
| Q4 24 | $110.4M | $22.6M | ||
| Q3 24 | $103.5M | — | ||
| Q2 24 | $97.0M | — | ||
| Q1 24 | $91.8M | — |
| Q4 25 | $12.5M | — | ||
| Q3 25 | $27.6M | — | ||
| Q2 25 | $16.7M | — | ||
| Q1 25 | $15.3M | $112.9M | ||
| Q4 24 | $3.7M | $-10.5M | ||
| Q3 24 | $8.7M | — | ||
| Q2 24 | $7.6M | — | ||
| Q1 24 | $2.2M | — |
| Q4 25 | 52.1% | — | ||
| Q3 25 | 52.7% | — | ||
| Q2 25 | 53.8% | — | ||
| Q1 25 | 52.1% | — | ||
| Q4 24 | 48.9% | — | ||
| Q3 24 | 51.1% | — | ||
| Q2 24 | 49.0% | — | ||
| Q1 24 | 48.4% | — |
| Q4 25 | 18.0% | — | ||
| Q3 25 | 22.9% | — | ||
| Q2 25 | 22.2% | — | ||
| Q1 25 | 22.8% | 70.2% | ||
| Q4 24 | 19.2% | -60.4% | ||
| Q3 24 | 22.1% | — | ||
| Q2 24 | 22.9% | — | ||
| Q1 24 | 23.3% | — |
| Q4 25 | 9.5% | — | ||
| Q3 25 | 21.8% | — | ||
| Q2 25 | 13.6% | — | ||
| Q1 25 | 13.4% | 71.2% | ||
| Q4 24 | 3.3% | -46.4% | ||
| Q3 24 | 8.4% | — | ||
| Q2 24 | 7.9% | — | ||
| Q1 24 | 2.4% | — |
| Q4 25 | $0.13 | — | ||
| Q3 25 | $0.29 | — | ||
| Q2 25 | $0.17 | — | ||
| Q1 25 | $0.16 | $1.90 | ||
| Q4 24 | $-11023.48 | $-0.15 | ||
| Q3 24 | $0.09 | — | ||
| Q2 24 | $0.09 | — | ||
| Q1 24 | $11023.54 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $84.8M | $274.8M |
| Total DebtLower is stronger | $715.7M | — |
| Stockholders' EquityBook value | $1.2B | $350.1M |
| Total Assets | $2.0B | $406.9M |
| Debt / EquityLower = less leverage | 0.61× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $84.8M | — | ||
| Q3 25 | $99.0M | — | ||
| Q2 25 | $103.3M | — | ||
| Q1 25 | $80.5M | $274.8M | ||
| Q4 24 | $54.1M | $128.0M | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $73.2M | — | ||
| Q1 24 | $28.2M | — |
| Q4 25 | $715.7M | — | ||
| Q3 25 | $279.4M | — | ||
| Q2 25 | $277.7M | — | ||
| Q1 25 | $277.5M | — | ||
| Q4 24 | $277.3M | — | ||
| Q3 24 | $602.1M | — | ||
| Q2 24 | $250.7M | — | ||
| Q1 24 | $534.2M | — |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | $350.1M | ||
| Q4 24 | $1.1B | $229.0M | ||
| Q3 24 | $769.8M | — | ||
| Q2 24 | $758.4M | — | ||
| Q1 24 | $420.6M | — |
| Q4 25 | $2.0B | — | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | $406.9M | ||
| Q4 24 | $1.5B | $271.6M | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $1.1B | — |
| Q4 25 | 0.61× | — | ||
| Q3 25 | 0.24× | — | ||
| Q2 25 | 0.25× | — | ||
| Q1 25 | 0.25× | — | ||
| Q4 24 | 0.25× | — | ||
| Q3 24 | 0.78× | — | ||
| Q2 24 | 0.33× | — | ||
| Q1 24 | 1.27× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $131.8M |
| Free Cash FlowOCF − Capex | — | $131.7M |
| FCF MarginFCF / Revenue | — | 83.0% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | 2.43× | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | — | ||
| Q3 25 | $29.7M | — | ||
| Q2 25 | $23.8M | — | ||
| Q1 25 | $28.4M | $131.8M | ||
| Q4 24 | $20.7M | $-23.2M | ||
| Q3 24 | $16.3M | — | ||
| Q2 24 | $7.1M | — | ||
| Q1 24 | $10.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $131.7M | ||
| Q4 24 | — | $-23.2M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 83.0% | ||
| Q4 24 | — | -102.7% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 2.43× | — | ||
| Q3 25 | 1.08× | — | ||
| Q2 25 | 1.42× | — | ||
| Q1 25 | 1.85× | 1.17× | ||
| Q4 24 | 5.62× | — | ||
| Q3 24 | 1.89× | — | ||
| Q2 24 | 0.93× | — | ||
| Q1 24 | 4.81× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LOAR
| Other | $76.8M | 58% |
| Commercial Aerospace | $21.2M | 16% |
| Business Jet And General Aviation | $17.6M | 13% |
| Defense | $16.2M | 12% |
STOK
Segment breakdown not available.
